Veldhuyzen van Zanten S, Hunt R H, Cockeram A, Schep G, Malatjalian D, Sidorov J, Matisko A, Jewell D
Department of Anatomic Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Am J Gastroenterol. 1998 Jan;93(1):5-10. doi: 10.1111/j.1572-0241.1998.005_c.x.
We compared the Helicobacter pylori eradication rate after a 14-day treatment with amoxicillin 500 mg t.i.d. and metronidazole 500 mg t.i.d. with or without omeprazole 20 mg once daily.
This was a randomized, controlled trial in which omeprazole was given in double-blind fashion. Patients with H. pylori-associated gastritis were enrolled in four centers in Canada from July 1991 to January 1994. Eradication of H. pylori was assessed by histological evaluation and culture of endoscopic biopsies obtained from the antrum and corpus of the stomach.
The H. pylori eradication rate was 73% (33 of 45) in the omeprazole-amoxicillin-metronidazole group, compared with 66% (31 of 47) in the amoxicillin-metronidazole group. This 7% difference was not statistically significant (p = 0.43, 95% confidence interval for difference -11% to 26%). Metronidazole primary resistance in the prestudy cultures was found more frequently in the omeprazole-amoxicillin-metronidazole group than in the amoxicillin-metronidazole group. Resistance to metronidazole was an important predictor of treatment failure. The H. pylori eradication rate was 61% (19 of 31) for patients infected with metronidazole-resistant H. pylori strains, compared with 91% (30 of 33) eradication for those infected with metronidazole-sensitive strains (p < 0.01). Vaginal candidiasis was reported in four patients.
The H. pylori eradication rate was higher (73%) for omeprazole-amoxicillin-metronidazole than for the dual antibiotic therapy given without omeprazole (66%); however, this difference was not statistically significant. Metronidazole resistance significantly reduces H. pylori eradication rates.
我们比较了采用阿莫西林500毫克每日三次和甲硝唑500毫克每日三次,联合或不联合每日一次20毫克奥美拉唑进行14天治疗后的幽门螺杆菌根除率。
这是一项随机对照试验,其中奥美拉唑采用双盲方式给药。1991年7月至1994年1月期间,加拿大四个中心招募了幽门螺杆菌相关性胃炎患者。通过对取自胃窦和胃体的内镜活检组织进行组织学评估和培养来评估幽门螺杆菌的根除情况。
奥美拉唑-阿莫西林-甲硝唑组的幽门螺杆菌根除率为73%(45例中的33例),而阿莫西林-甲硝唑组为66%(47例中的31例)。这7%的差异无统计学意义(p = 0.43,差异的95%置信区间为-11%至26%)。在研究前的培养中,奥美拉唑-阿莫西林-甲硝唑组比阿莫西林-甲硝唑组更频繁地发现甲硝唑原发耐药。对甲硝唑耐药是治疗失败的重要预测因素。感染甲硝唑耐药幽门螺杆菌菌株的患者的幽门螺杆菌根除率为61%(31例中的19例),而感染甲硝唑敏感菌株的患者的根除率为91%(33例中的30例)(p < 0.01)。有4例患者报告了阴道念珠菌病。
奥美拉唑-阿莫西林-甲硝唑的幽门螺杆菌根除率(73%)高于不使用奥美拉唑的双联抗生素疗法(66%);然而,这种差异无统计学意义。甲硝唑耐药显著降低幽门螺杆菌根除率。